CAMBRIDGE, Massachusetts — ProFound Therapeutics has secured an investment commitment of up to $35 million from the Gates Foundation to search for new biological targets connected to preeclampsia and eclampsia.
The agreement, announced on 27 August, begins with $20 million. A further $15 million depends on experimental milestones, according to Fierce Biotech.
Preeclampsia involves high blood pressure during pregnancy and can progress to organ injury, seizures, premature delivery or death. ProFound and the foundation estimate that the related conditions affect about 10 million women annually and contribute to approximately 76,000 maternal deaths.
ProFound plans to analyse proteins found in placental tissue and blood serum from women with and without the conditions. Its platform is designed to investigate an expanded or “dark” proteome: proteins that conventional approaches may not have identified or characterised.
The company also intends to develop an agentic artificial-intelligence system to help connect candidate proteins with biological functions and possible drug targets.
That description does not mean an autonomous AI will discover a medicine ready for patients. Computational findings must be reproduced in laboratories, linked to disease mechanisms, tested for safety and eventually evaluated in clinical trials.
The project’s attention to placental biology is significant because female-specific conditions receive a small portion of global medical research spending. Preeclampsia also causes a disproportionate burden where antenatal screening, laboratory services and emergency obstetric care are limited.
Any resulting test or treatment must therefore be designed for the health systems facing the greatest need. A biomarker requiring expensive equipment or refrigerated supply chains may have limited impact in clinics without reliable electricity or laboratory staff.
The research also depends on sensitive pregnancy samples. ProFound should disclose consent processes, sample geography, demographic representation and governance of genomic or proteomic data. A model trained on narrow populations may perform unevenly elsewhere.
The investment commitment is not a grant of $35 million delivered immediately, and the company’s outcome estimates remain programme-reported. Reporting should preserve those distinctions.
ProFound’s programme represents an important bet: that neglected proteins and AI-assisted analysis can reveal biology missed by conventional research. Its success will not be measured by the number of targets generated, but by whether rigorous validation produces affordable tools that prevent women and babies from dying.
Join the discussion